Neuroleptic malignant syndrome in advanced Parkinson's disease
- 1 September 2001
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 16 (5) , 960-962
Abstract
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa. © 2001 Movement Disorder Society.Keywords
This publication has 17 references indexed in Scilit:
- Clozapine-induced neuroleptic malignant syndrome: an interaction between dopaminergic and purinergic systems?Journal of Psychopharmacology, 1999
- Serotonin syndromeNeurology, 1995
- A proposed new nomenclature for 5-HT receptorsTrends in Pharmacological Sciences, 1993
- Fluoxetine and neuroleptic malignant syndromeBiological Psychiatry, 1990
- “On‐Off”–induced lethal hyperthermiaMovement Disorders, 1989
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984
- Fatal hyperpyrexia after withdrawal of levodopaNeurology, 1984
- Neuroleptic malignant syndromeNeurology, 1981
- Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitorNeurology, 1960